Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Affiliations

• ¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
• ² Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, USA.
• ³ Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA.
• ⁴ Global Epidemiology, Boehringer Ingelheim International GmbH (Germany) DE, Berlin, Germany.
• ⁵ Global Medical Affairs, Lilly Deutschland GmbH, Bad Homburg, Germany.
• ⁶ Division of Renal (Kidney) Medicine, Brigham and Women's Hospital, Boston, MA, USA.
• ⁷ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA. epatorno@bwh.harvard.edu.